Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Nordisk A/S Lawsuit – NVO
12:47pm, Thursday, 30'th Jan 2025
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S (NVO) Shareholders
12:30pm, Thursday, 30'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO
12:00pm, Thursday, 30'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NASDAQ:NVO). Such invest
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S (NVO) of a Class Action Lawsuit and an Upcoming Deadline
11:30am, Thursday, 30'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws
Novo Nordisk A/S Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
11:00am, Thursday, 30'th Jan 2025
LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo"
Novo Nordisk says it has not yet posted details about new CagriSema trial
10:30am, Thursday, 30'th Jan 2025
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S(NVO) Shareholders
10:30am, Thursday, 30'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nor
Novo Nordisk's new CagriSema obesity drug trial to begin on Feb. 10, clinicaltrials.gov entry shows
09:43am, Thursday, 30'th Jan 2025
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a www.clinicaltrials.gov entry.
NVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
05:45am, Thursday, 30'th Jan 2025
NEW YORK , Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class perio
Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
09:30pm, Wednesday, 29'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Novo Nordisk
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
06:50pm, Wednesday, 29'th Jan 2025
Novo Nordisk (NVO) concluded the recent trading session at $84.03, signifying a -1.36% move from its prior day's close.
Class Action Filed Against Novo Nordisk A/S (NVO) - March 25, 2025 Deadline to Join - Contact Levi & Korsinsky
04:15pm, Wednesday, 29'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws
